Acceleron Pharma Inc. (NASDAQ:XLRN) reported Q2 2017 earnings this Morning, coming in at ($0.77) per share, missing Wall Street’s estimates of ($0.63) per Share. Revenue for the quarter came in at $3.10 million missing the streets estimates of $3.69 million
Analyst Coverage For Acceleron Pharma Inc. (NASDAQ:XLRN)
These are 1 Sell Rating, 4 Hold Ratings, 10 Buy Ratings .
The current consensus rating for Acceleron Pharma Inc. (NASDAQ:XLRN) is Buy (Score: 2.60) with a consensus target price of $42.54 , a potential (28.05% upside)Recent Insider Trading for Acceleron Pharma Inc. (NASDAQ:XLRN)
- On 7/5/2017 Kevin F Mclaughlin, CFO, sold 34,400 with an average share price of $32.00 per share and the total transaction amounting to $1,100,800.00.
- On 7/5/2017 Matthew L Sherman, EVP, sold 16,000 with an average share price of $32.00 per share and the total transaction amounting to $512,000.00.
- On 7/5/2017 Ravindra Kumar, SVP, sold 937 with an average share price of $32.00 per share and the total transaction amounting to $29,984.00.
- On 1/4/2017 Kevin F Mclaughlin, CFO, sold 1,700 with an average share price of $27.45 per share and the total transaction amounting to $46,665.00.
- On 1/4/2017 Matthew L Sherman, EVP, sold 2,000 with an average share price of $27.46 per share and the total transaction amounting to $54,920.00.
- On 1/4/2017 Steven D Ertel, COO, sold 2,500 with an average share price of $27.44 per share and the total transaction amounting to $68,600.00.
Recent Trading for Acceleron Pharma Inc. (NASDAQ:XLRN) Shares of Acceleron Pharma Inc. closed the previous trading session at 33.22 up +0.15 0.45% with 287,195 shares trading hands.